Blood Purification Devices Market

A single HA380 haemoadsorption cartridge lists at GBP 450 to the NHS and a CytoSorb cartridge at GBP 920, according to NICE technology briefing MIB217, while Medicare pays USD 281.71 for an entire outpatient dialysis treatment in 2026, the base rate CMS finalised on 20 November 2025. Blood purification devices are the machines, filters, circuits and sorbent cartridges that clean blood outside the body; the Blood Purification Devices Market covers haemodialysis, continuous renal replacement therapy (CRRT), therapeutic apheresis and haemoperfusion. Douglas Insights puts the market at USD 15.43 billion in 2025 and USD 25.36 billion in 2035, a revenue CAGR of 5.09%. The arithmetic is 588.42 million extracorporeal sessions at an average device revenue of USD 26.22 per session, which equals USD 15.43 billion. Sessions grow 3.46% a year and revenue per session 1.58%. The study belongs to our renal care devices coverage, and every input is listed under the Douglas Insights research methodology.

Which blood purification devices fall inside this extracorporeal study, and which stay out?

Blood purification devices in this study form five groups serving 588.42 million sessions in 2025. The groups are dialyzers and bloodlines, haemodialysis and haemodiafiltration machines, CRRT systems and sets, therapeutic apheresis systems and sets, and haemoperfusion and haemoadsorption cartridges. Each one moves blood through an external circuit. That circuit is the boundary test.

Peritoneal dialysis is left out, because the peritoneum filters inside the body and no blood leaves the patient. Dialysis water plants, acid and bicarbonate concentrates and the dialysis service itself also sit outside. Donor plasma collection for fractionation is excluded; only therapeutic apheresis counts. The clinical uses covered are chronic kidney failure, acute kidney injury, sepsis and critical care, autoimmune and neurological disease, and poisoning and liver failure. End users are dialysis centres, hospital intensive care units and home care. Intravenous iron given during dialysis belongs to the Iron Supplements Market report, not here.

Is the blood purification market simply the dialysis equipment market under another name?

No: the shared ground is 75.8% of value. Blood purification devices overlap with the Dialysis Equipment Market only on haemodialysis, which supplies 75.8% of value here; this study adds 19.20 million CRRT, apheresis and haemoperfusion sessions and drops the peritoneal dialysis solutions and cyclers that the sibling report counts.

The sibling report counts about 624 million dialysis treatments including home peritoneal exchanges. This one counts 588.42 million extracorporeal sessions. Acute kidney injury therapy in the ICU, plasma exchange for myasthenia gravis and cytokine adsorption in septic shock never appear in a dialysis equipment count, yet they carry 24.2% of blood purification value. A buyer sizing a dialyzer plant needs both studies. The haemodialysis core is shared; the edges are not.

How much do blood purification devices cost per session, from a dialyzer to a CRRT circuit?

Device revenue per blood purification session averages USD 26.22 in 2025. The band is wide: about USD 20.55 for a chronic haemodialysis treatment, USD 138 for a CRRT day, USD 236 for a haemoperfusion session and USD 418 for an apheresis procedure. Volume sits at the cheap end of that band.

Douglas Insights estimates that dialyzers and bloodlines take USD 13.90 of each haemodialysis treatment and the amortised machine USD 6.65. Disposables dominate the bill. Fresenius Medical Care sold about 171 million dialyzers in 2025, equal to 30.0% of the 569.22 million haemodialysis sessions in our count, so single-use filters are a volume business measured in hundreds of millions of units.

Medicare sets the ceiling for US budgets. The calendar year 2026 end-stage renal disease prospective payment system (ESRD PPS) base rate is USD 281.71 per treatment, up USD 7.89 from USD 273.82, per the CMS final rule fact sheet, and that one bundle pays for staff, drugs, laboratory tests and every disposable. A device spend of USD 20.55 equals 7.3% of the 2026 bundle. Small slice, hard ceiling.

Sorbent prices sit an order of magnitude higher. NICE lists the D2000 plasma adsorption cartridge at GBP 1,785, beside GBP 450 for the HA330 or HA380 and GBP 920 for CytoSorb, all excluding VAT. Our blended haemoperfusion figure of USD 236 assumes most volume runs on lower-priced maintenance cartridges; that is a modelling assumption, not a published price. Revenue per blood purification session rises 1.58% a year through mix, as haemodiafiltration, high-flux filters and sorbents gain share, against a 2.9% rise in the 2026 Medicare base rate.

Which blood purification product segment makes the money, and which grows fastest?

Dialyzers and bloodlines make the money: USD 7.91 billion, or 51.3% of blood purification device value in 2025, because each of 569.22 million haemodialysis sessions discards a filter and a circuit. Haemoperfusion and haemoadsorption cartridges grow fastest, at 9.42% a year to 2035.

Dialyzers and bloodlines hold 51.3% at USD 7.91 billion, the single-use spine of every haemodialysis treatment, and grow 4.38% a year with patient numbers. Haemodialysis and haemodiafiltration machines carry USD 3.78 billion, a 24.5% share, growing 3.94% because a machine serves several patients a day for 7 to 10 years. CRRT systems and sets take USD 1.76 billion, or 11.4%, priced per ICU day rather than per session, and expand 6.18% a year. Therapeutic apheresis systems and sets add USD 1.02 billion (6.6%) and rise 6.57% as plasma exchange indications widen in neurology. Haemoperfusion and haemoadsorption cartridges hold 6.2% at USD 956.6 million.

The fastest blood purification segment earns its 9.42% rate from price and spread together. A cartridge is worth about 17 times a haemodialysis disposable set, and our model places most cartridge volume in Chinese dialysis wards that pair haemoperfusion with haemodialysis. Douglas Insights projects the cartridge line at USD 2.35 billion by 2035, ahead of apheresis at USD 1.92 billion.

Why are blood purification session counts climbing faster than kidney failure alone?

Blood purification sessions grow 3.46% a year because four separate patient pools are expanding at once: chronic haemodialysis adds 2.31 points, intensive care CRRT 0.52, haemoperfusion adoption 0.41 and therapeutic apheresis 0.22. Price mix adds another 1.58 points on top.

Chronic kidney failure is the base load. About 4.5 million people regularly undergo dialysis worldwide, according to Fresenius Medical Care, which alone cared for around 292,000 patients in roughly 3,600 clinics and delivered more than 44 million treatments in 2025. That works out at 150.7 treatments per patient a year, close to the thrice-weekly schedule. Douglas Insights models 88% of the global dialysis population on haemodialysis at an average of 142 sessions, lower than the Fresenius ratio because twice-weekly schedules persist in lower-income markets; the result is 562.32 million chronic sessions. Diabetes, hypertension and ageing push that pool up, and the pool contributes 2.31 points of the 3.46% volume leg.

Intensive care is the second engine. Our model counts 12.7 million CRRT treatment days in 2025, priced at USD 138 per day in devices, and expects them to contribute 0.52 points of growth as acute kidney injury in sepsis and cardiac surgery is treated earlier. The supply side changed shape on 31 January 2025, when Baxter completed the USD 3.80 billion sale of its Kidney Care business to Carlyle, creating Vantive, a dedicated company whose PrisMax platform runs CRRT and therapeutic plasma exchange. A focused owner of a leading ICU platform tends to sell harder into acute care. In our model each extra ICU day adds disposable revenue, not just machine hours.

Sorbents are the third engine. Haemoperfusion and haemoadsorption sessions reach an estimated 4.05 million in 2025, only 0.69% of blood purification sessions, yet they add 0.41 points of volume growth. CytoSorbents reports more than 300,000 cumulative CytoSorb treatments and distribution in over 70 countries, a base that took more than a decade to build.

Therapeutic apheresis is the fourth. Plasma exchange and selective adsorption columns treat myasthenia gravis, Guillain-Barre syndrome and antibody-mediated transplant rejection; Douglas Insights tallies 2.45 million apheresis procedures in 2025 and assigns them 0.22 points of the volume leg. Apheresis is small in sessions but runs at USD 418 per procedure, the highest device spend of any modality in our tracker. Together the four legs sum to exactly 3.46%, and none of them depends on a single payer.

Which headwinds hold back haemoadsorption and apheresis inside blood purification?

Three headwinds remove 0.86 points from blood purification volume growth, cutting a gross 4.32% to the 3.46% base. They are fixed dialysis bundles (0.38 points), thin trial evidence for sorbents (0.27) and unpaid access in low-income markets (0.21).

Bundled payment squeezes every disposable. The 2026 Medicare rate of USD 281.71 must cover a whole treatment, and CMS also ended the ESRD Treatment Choices Model early because it did not deliver the expected home dialysis results or savings, per the same final rule. Clinics answer with tender pressure on dialyzers and slower machine replacement. Douglas Insights removes 0.38 points of blood purification volume growth for this ceiling.

Evidence is the second hurdle. The FDA issued a De Novo denial for CytoSorbents’ DrugSorb-ATR antithrombotic removal system in April 2025 and upheld it on appeal in August 2025, citing a need for more information to support the label rather than safety, according to the company’s results release; a new application is planned with no date set. Each such delay keeps haemoadsorption off US cardiac surgery lists. We remove 0.27 points for it.

Access is the third. Of 4.5 million people on dialysis, most live in countries without full public payment, and untreated kidney failure in Africa and South Asia caps session growth regardless of device supply. Douglas Insights deducts 0.21 points. Twice-weekly haemodialysis and dialyzer reuse in price-sensitive clinics also lower disposable use per patient.

Which blood purification companies supply the machines, filters and cartridges?

Fresenius Medical Care leads blood purification with about 27.4% of 2025 device value, Douglas Insights estimates, built on roughly half of the world’s haemodialysis machine base and 171 million dialyzers sold. The top three, adding Vantive and B. Braun, hold an estimated 46.8%.

Fresenius Medical Care is vertically integrated: its machines and dialyzers run inside its own clinic network of around 292,000 patients, a captive outlet no rival matches. Vantive became a standalone dialysis and acute therapy company after Baxter closed the USD 3.80 billion sale on 31 January 2025, as disclosed in Baxter’s quarterly filing; its PrisMax system covers CRRT modes and therapeutic plasma exchange, which anchors its acute care share. B. Braun competes with the Dialog iQ platform, which offers both haemodialysis and haemodiafiltration.

Nikkiso built Japan’s first domestic dialysis machine in 1969 and holds over 50% of the Japanese dialysis machine market, alongside CRRT and apheresis lines. Asahi Kasei Medical developed hollow fibre dialysis membranes in 1974, and its blood purification devices are reimbursed for over 30 diseases in Japan. Jafron Biomedical supplies disposable HA haemoperfusion cartridges. Terumo Blood and Cell Technologies sells the Spectra Optia apheresis system, used for red blood cell exchange in sickle cell disease. CytoSorbents earned USD 37.1 million in 2025, about 0.24% of blood purification value, with a 71% gross margin. Shares beyond the top three are Douglas Insights estimates anchored on disclosed revenue where it exists.

Where are blood purification sessions concentrated, and which region adds most value?

Asia Pacific is the largest blood purification region at USD 5.34 billion in 2025, 34.6% of value, and also the fastest at 6.62% a year. Our model adds haemodialysis capacity in China and India and places most haemoperfusion volume in China.

North America follows with USD 4.74 billion (30.7%), priced high but capped by the Medicare bundle, and grows 4.12% to USD 7.09 billion in 2035. Europe holds USD 3.72 billion, a 24.1% share, with the slowest rate at 3.48% because haemodialysis penetration is mature and haemodiafiltration is already common. Asia Pacific reaches USD 10.13 billion by 2035. Latin America is worth USD 972.0 million and grows 5.71% as dialysis access widens in its larger economies. The Middle East and Africa add USD 663.5 million in 2025, rising 6.14% a year to USD 1.20 billion.

The wildcard is Africa. Untreated kidney failure there is large, and any public dialysis programme that pays for sessions would lift Middle East and Africa blood purification spending faster than our 6.14% base rate. Douglas Insights forecasts Asia Pacific to add USD 4.80 billion over the decade, more than North America and Europe add together at USD 3.87 billion.

Which rules decide blood purification reimbursement and market entry?

Three rule sets shape blood purification revenue, led by the US ESRD PPS bundle at USD 281.71 per treatment for 2026. The others are CE class IIb conformity for sorbent cartridges in Europe, and FDA De Novo or 510(k) review for new US devices. Payment rules set the price; device rules set the timing.

The CY 2026 rule covers about 7,600 ESRD facilities and raises total payments about 2.2%, with freestanding facilities at about 2.2% and hospital-based units at about 1.5%, per CMS. It keeps a training add-on for home and self-dialysis modalities. In Europe, the HA330, HA380 and CytoSorb cartridges are CE-marked class IIb medical devices, the HA series for removing endogenous and exogenous pathogenic substances and CytoSorb for cytokines, bilirubin and myoglobin. In the US, DrugSorb-ATR holds two FDA Breakthrough Device Designations but no authorisation, which shows how far a Breakthrough label sits from a sale. For blood purification makers, the US label is the slowest gate in the market.

What if haemoadsorption stalls or home haemodialysis surges: blood purification in 2035?

Blood purification devices reach USD 25.36 billion by 2035 in the base case, on 3.46% volume and 1.58% price growth; a slower path gives USD 21.82 billion and a faster one USD 29.49 billion. The gap between the two outer cases is USD 7.67 billion.

The slower case runs volume at 2.40% and price at 1.10%: Medicare bundles stay tight after the 2026 rule, sorbent approvals slip again and dialyzer tenders keep pressing prices. The faster case runs volume at 4.60% and price at 2.00%: a US haemoadsorption authorisation, wider CRRT use in sepsis and haemodiafiltration replacing standard haemodialysis across Asia. The base case sits between them with 826.8 million sessions in 2035.

Volume is the lever that matters. Adding 1 point to blood purification session growth, with price unchanged, lifts 2035 value by USD 2.56 billion. Our 5.09% revenue CAGR sits below the 5.40% to 8.01% spread of outside forecasts, because those scopes fold in water plants, peritoneal dialysis or donor plasma equipment that this study excludes.

Douglas Exclusive: the Extracorporeal Session Tracker for blood purification

The Extracorporeal Session Tracker is a Douglas Insights model, not an official register, built from 15 sourced inputs. They comprise 7 from Fresenius Medical Care and Baxter disclosures, 3 CMS payment figures, 3 NICE cartridge prices and 2 CytoSorbents figures. It counts blood purification sessions by modality and pairs each with device revenue per session.

The finding is a mismatch between volume and value. Non-dialysis modalities are 3.26% of blood purification sessions but 24.2% of device value, because a CRRT day, an apheresis run or a cartridge earns about 7 to 20 times a haemodialysis treatment. Haemoperfusion alone turns 0.69% of sessions into USD 955.8 million. Growth investment should follow the value per session, not the session count.

How we rebuilt 588.42 million blood purification sessions from clinic and payer counts?

Douglas Insights calculates the 2025 blood purification base as 588.42 million sessions times USD 26.22 of device revenue, equal to USD 15.43 billion, across 5 modalities, 5 regions and 15 sourced inputs. Every number is computed in one model.

Chronic haemodialysis: 4.5 million dialysis patients x 88% on haemodialysis x 142 sessions = 562.32 million. Acute work adds 6.9 million intermittent sessions and 12.7 million CRRT days; apheresis adds 2.45 million and haemoperfusion 4.05 million. Values: 569.22 million haemodialysis sessions x USD 20.55 = USD 11.70 billion; CRRT 12.7 x USD 138 = USD 1.75 billion; apheresis 2.45 x USD 418 = USD 1.02 billion; haemoperfusion 4.05 x USD 236 = USD 955.8 million. Regions sum to USD 15.43 billion in 2025 and USD 25.36 billion in 2035.

Cross-checks: the Fresenius ratio of 150.7 treatments per patient sits 6.1% above our 142-session average, a gap explained by twice-weekly schedules outside rich markets. Fresenius dialyzer sales equal 30.0% of our haemodialysis sessions, consistent with its roughly 50% machine share once reuse and rival filters are counted. Outside 2025 estimates range from USD 3.69 billion for narrow filtration scopes to USD 23.5 billion for scopes that include water and peritoneal equipment; ours lands between them.

Sources

1. Centers for Medicare and Medicaid Services CY 2026 ESRD PPS final rule fact sheet (2025)
2. Fresenius Medical Care Facts and figures (2026)
3. Baxter International (SEC EDGAR) Form 10-Q, quarter ended 31 March 2025 (2025)
4. CytoSorbents Fourth quarter and full year 2025 results (2026)
5. NICE MIB217 cytokine adsorption devices (2020)
6. Nikkiso Medical products (2026)